Alfred Lee, MD, PhD
DownloadHi-Res Photo
Cards
Appointments
Hematology
Primary
Titles
Director, Hematology/Oncology Fellowship Program; Chief, Classical Hematology Program
Contact Info
Appointments
Hematology
Primary
Titles
Director, Hematology/Oncology Fellowship Program; Chief, Classical Hematology Program
Contact Info
Appointments
Hematology
Primary
Titles
Director, Hematology/Oncology Fellowship Program; Chief, Classical Hematology Program
Contact Info
About
Titles
Professor of Medicine (Hematology)
Director, Hematology/Oncology Fellowship Program; Chief, Classical Hematology ProgramBiography
Dr. Alfred Ian Lee is Professor of Medicine (Hematology) and Program Director for the hematology/oncology fellowship program. He received his MD/PhD from the Yale School of Medicine in 2004. Dr. Lee completed residency in internal medicine at Brigham & Women’s Hospital, where he served as Chief Medical Resident, followed by a fellowship in hematology/oncology at Dana-Farber Cancer Institute. His primary academic interests are classical hematology, thrombosis, and medical education. He has received such honors as the Charles W. Bohmfalk Prize for teaching in the basic sciences, the Leah M. Lowenstein Award for excellence in the promotion of humane and egalitarian medical education, the Yale Cancer Center Award for Mentorship Excellence, and the David J. Lefell Prize for Clinical Excellence.
Appointments
Hematology
ProfessorPrimary
Other Departments & Organizations
- Classical Hematology at Smilow Cancer Hospital
- Developmental Therapeutics
- Hematology
- Internal Medicine
- Leukemia & Lymphoma Program
- Yale Cancer Center
- Yale Medicine
- Yale Ventures
- YCC Diversity, Equity, and Inclusion
Education & Training
- Fellowship
- Dana Farber Cancer Institute (2011)
- Chief Medical Resident
- Brigham & Women's Hospital (2010)
- Residency
- Brigham & Women's Hospital (2007)
- MD
- Yale School of Medicine (2004)
- PhD
- Yale University (2003)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Alfred Lee's published research.
Publications Timeline
A big-picture view of Alfred Lee's research output by year.
Alexander B. Pine, MD, PhD
Nikolai Podoltsev, MD, PhD
George Goshua, MD, MSc, FACP
Ayesha Butt, MBBS
Natalia Neparidze, MD
Noffar Bar, MD
77Publications
1,829Citations
Publications
2024
International medical graduates (IMG) representation at international oncology conference meetings.
Roy A, Bakouny Z, Dizman N, Ozay Z, Mohan Lal B, Nawfal R, Eid M, El Hajj Chehade R, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall A, Murphy M, Owonikoko T, Lee A, CHOUEIRI T. International medical graduates (IMG) representation at international oncology conference meetings. Journal Of Clinical Oncology 2024, 42: 9000-9000. DOI: 10.1200/jco.2024.42.16_suppl.9000.Peer-Reviewed Original ResearchConceptsInternational medical graduatesAmerican medical graduatesASCO Annual MeetingMedical graduatesFaculty rolesMedical schoolsAmerican Society of Clinical Oncology (ASCOUS institutionsInternational oncology meetingsOncology workforceUnder-recognitionOncology meetingsSelection of presentationsAssess factorsMultivariate analysisPracticing oncologistsUS-basedASCOConference meetingsAcademic rankOriginal researchHighest proportionPodium presentationsAmerican SocietyUnited StatesLongitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program.
Srikumar T, Stempel J, Goldberg S, Podoltsev N, Braun D, Lee A, Sanft T. Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2024, 42: 9004-9004. DOI: 10.1200/jco.2024.42.16_suppl.9004.Peer-Reviewed Original ResearchConceptsNeeds assessmentLongitudinal curriculumPatient Health Questionnaire 2Score of self-efficacyGeneral Self-Efficacy ScaleFellowship programsBaseline needs assessmentFaculty-led sessionsProfessional boundary settingSelf-Efficacy ScaleLevels of depressionProfessional developmentFirst-year fellowsDidactic sessionsPrevent burnoutChi-square testAcademic yearDebriefing sessionsQuestionnaire 2Baseline assessmentSelf-efficacyProfessional development skillsDepressed moodLeadership skillsBurnoutCost‐effectiveness of sutimlimab in cold agglutinin disease
Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost‐effectiveness of sutimlimab in cold agglutinin disease. American Journal Of Hematology 2024, 99: 1475-1484. PMID: 38733355, DOI: 10.1002/ajh.27358.Peer-Reviewed Original ResearchAltmetricConceptsPrimary cold agglutinin diseaseCold agglutinin diseaseStandard-of-careIncremental cost-effectiveness ratioUS willingness-to-pay thresholdRare autoimmune hemolytic anemiaPhase 3 studyWillingness-to-pay thresholdsAutoimmune hemolytic anemiaTime-limited treatmentHuman monoclonal antibodyCold-reactive antibodiesBinding to red blood cellsFollow-up dataCost-effectiveness ratioComplement-mediated hemolysisDeterministic sensitivity analysisHealth resource utilizationProbabilistic sensitivity analysesTransfusion-dependentClinical remissionTransfusion supportImprove quality of lifeRed blood cellsHemolytic anemiaProviding 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment
Butt A, Christian J, Kress A, Lu B, Hurwitz M, Goldberg S, Podoltsev N, Gilkes L, Lee A. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment. Journal Of Cancer Education 2024, 39: 325-334. PMID: 38430454, DOI: 10.1007/s13187-024-02414-z.Peer-Reviewed Original ResearchAltmetricConceptsFull-time equivalent supportFull-time equivalentAmerican Council for Graduate Medical EducationCore facultyFellowship programsFellowship educationGraduate Medical EducationImprove job satisfactionCF programPotential unintended consequencesMedical educationSalary supportSurvey respondentsIncreased participationMedical oncologyUnintended consequencesSubspecialty fellowshipsIncreased senseSense of commitmentJob satisfactionFellowshipEducationFaculty involvement
2023
Comprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchConceptsHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test resultsThe Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence
Muradashvili T, Restrepo V, Alameddine D, Soliman S, Feinn R, Chaar C, Lee A, Pine A. The Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence. Blood 2023, 142: 5540. DOI: 10.1182/blood-2023-191084.Peer-Reviewed Original ResearchConceptsFirst VTE recurrenceDeep venous thrombosisFirst venous thromboembolismRecurrent VTE eventsVTE recurrenceVenous thromboembolismPulmonary embolismAnticoagulation regimenVTE eventsAnticoagulant regimenFirst recurrenceINR targetSecond recurrenceExact testFirst recurrent venous thromboembolismInferior vena cava atresiaLarge tertiary academic hospitalUnprovoked first venous thromboembolismMajor public health hazardDifferent anticoagulant agentsInterruption of anticoagulationCardiovascular risk factorsMay-Thurner syndromePatients 18 yearsRecurrent venous thromboembolismMultimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders
Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.Peer-Reviewed Original ResearchConceptsBleeding tendencyBleeding disorderPlatelet markersPlatelet aggregometryMass cytometryPlatelet functionPlatelet disordersSingle-center prospective studyLow-risk groupAbnormal bleeding tendencyQualitative platelet disordersLarge patient cohortQuantitative platelet disordersCommon underlying causeGenetic variantsMultimodality evaluationTotal patientsRisk stratificationLaboratory suspicionPlatelet dysfunctionProspective studyPatient cohortUnivariate analysisPlatelet volumeRisk groupsSetting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States
Ito S, Chetlapalli K, Potnis K, Richmond R, Wang D, Lee A, Goshua G. Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States. Blood 2023, 142: 5042. DOI: 10.1182/blood-2023-188063.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTreatment-experienced patientsParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitIncremental cost-effectiveness ratioNursing timeExtravascular hemolysisNocturnal hemoglobinuriaPhase III study resultsTreatment-experienced adult patientsTransfusion-associated adverse eventsCost-effective therapeutic optionAnti-C5 therapyComplement inhibition therapyComplement inhibitor therapyHealth resource utilizationCare of patientsIndirect medical costsComplement component 5Clinical trial dataLife-threatening hematological disorderCost-effectiveness ratioBreakthrough therapy designationProbabilistic sensitivity analysesFirst cost-effectiveness analysisCost-effectiveness analysisCharacterizing Outpatient Classical Hematology Referrals at an Academic Healthcare System
Chang E, Kress A, Ackermann F, Fradkin M, Halene S, Herbert E, Shomsky L, Sudhakar L, Lee A, Bona R. Characterizing Outpatient Classical Hematology Referrals at an Academic Healthcare System. Blood 2023, 142: 7196. DOI: 10.1182/blood-2023-186065.Peer-Reviewed Original ResearchConceptsIron deficiency anemiaAdvanced practice providersManual chart reviewChart reviewDeficiency anemiaHematology referralCommon diagnosisNew patientsAnemia groupDiagnosis levelClinical sitesIron deficiency groupAcademic healthcare systemHealthcare systemICD-10 codesNew patient encountersICD diagnosis codesSubstantial patient populationLevel 1 casesLevel 1Available cliniciansThrombosis groupAdditional patientsLevel 3New referralsCost-Effectiveness of Sutimlimab Versus Standard-of-Care in Transfusion Dependent Patients with Primary Cold Agglutinin Disease in the United States
Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost-Effectiveness of Sutimlimab Versus Standard-of-Care in Transfusion Dependent Patients with Primary Cold Agglutinin Disease in the United States. Blood 2023, 142: 2316. DOI: 10.1182/blood-2023-187270.Peer-Reviewed Original ResearchConceptsPrimary cold agglutinin diseaseCold agglutinin diseaseIncremental cost-effectiveness ratioTransfusion-dependent patientsIncremental net monetary benefitProbabilistic sensitivity analysesDistributional cost-effectiveness analysisAnemia severityBody weightPhase 3 clinical studiesHealth resource utilizationRed blood cell destructionDisease-specific mortalityHistory of transfusionAutoimmune hemolytic anemiaMarkov state transition modelCare of patientsHumanized monoclonal antibodyLower body weightBlood cell destructionCost-effectiveness ratioFDA package insertsCold-reactive antibodiesBase-case analysisCost-effectiveness analysis
Academic Achievements and Community Involvement
activity Member
Peer Review Groups and Grant Study SectionsNational Comprehensive Cancer Network Cancer-Associated Venous Thromboembolic Disease PanelDetails2015 - Presentactivity Member
Professional OrganizationsCommittee on Training, American Society of HematologyDetails12/13/2015 - Presentactivity Chair
Professional OrganizationsRecruitment & Retention Working Group, American Society of HematologyDetails05/31/2017 - Presentactivity Member
Peer Review Groups and Grant Study SectionsNIH ClinGen Hemostasis/Thrombosis Expert PanelDetails01/30/2019 - Presentactivity Faculty Member
Professional OrganizationsMedical Educators Institute, American Society of HematologyDetails08/26/2019 - Present
Clinical Care
Overview
Alfred Ian Lee, MD, PhD, is Professor of Medicine (Hematology) and Program Director for the hematology/oncology fellowship program. He received his MD/PhD from the Yale School of Medicine in 2004. Dr. Lee completed residency in internal medicine at Brigham & Women’s Hospital, where he served as Chief Medical Resident, followed by a fellowship in hematology/oncology at Dana-Farber Cancer Institute. His primary academic interests are classical hematology, thrombosis, and medical education.
He has received such honors as the Charles W. Bohmfalk Prize for teaching in the basic sciences, the Leah M. Lowenstein Award for excellence in the promotion of humane and egalitarian medical education, the Yale Cancer Center Award for Mentorship Excellence, and the David J. Lefell Prize for Clinical Excellence.
Clinical Specialties
Hematology; Hematology & Oncology
Fact Sheets
Anemia
Learn More on Yale MedicineBleeding Disorders
Learn More on Yale MedicineHodgkin's Lymphoma
Learn More on Yale MedicineMyeloproliferative Neoplasms
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- June 12, 2024
Yale Medical Oncology-Hematology Fellowship Graduation 2024
- May 28, 2024
Annual Fellows Research Day 2024
- May 20, 2024
American Society of Hematology Selects Jennifer Afranie-Sakyi, MD to Receive the 2024 ASH Minority Hematology Fellow Award
- April 15, 2024
Multidisciplinary CMCO Making Strides
Related Links
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.